Key result
Elevated NT-proBNP (≥49 pg/mL) independently predicted mortality in tobacco smokers without known cardiovascular disease, conferring a 2.19-fold increased risk of death.
Why the study?
Does elevated NT-proBNP predict mortality in tobacco smokers without known cardiovascular disease?
Cohort (n=796)
No
Does elevated NT-proBNP predict mortality in tobacco smokers without known cardiovascular disease?
Hazard Ratio: 2.19 (95% CI 1.07–4.46)
Absolute Event Rate: 7.3% vs 3.3%
p-value: p=0.031
Elevated NT-proBNP is an independent predictor of mortality in tobacco smokers without known cardiovascular disease, conferring a 2.2-fold increased risk of death.
NT-proBNP may identify higher-risk smokers without known CVD; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Tobacco use is associated with an increased prevalence of cardiovascular disease. N-terminal pro-brain natiuretic peptide (NT-proBNP), a widely available biomarker that is associated with cardiovascular outcomes in other conditions, has not been investigated as a predictor of mortality in tobacco smokers. We hypothesized that NT-proBNP would be an independent prognostic marker in a cohort of well-characterized tobacco smokers without known cardiovascular disease. METHODS: Clinical data from 796 subjects enrolled in two prospective tobacco exposed cohorts was assessed to determine factors associated with elevated NT-proBNP and the relationship of these factors and NT-proBNP with mortality. RESULTS: Subjects were followed for a median of 562 (IQR 252-826) days. Characteristics associated with a NT-proBNP above the median (≥49 pg/mL) were increased age, female gender, and decreased body mass index. By time-to-event analysis, an NT-proBNP above the median (≥49 pg/mL) was a significant predictor of mortality (log rank p = 0.02). By proportional hazard analysis controlling for age, gender, cohort, and severity of airflow obstruction, an elevated NT-proBNP level (≥49 pg/mL) remained an independent predictor of mortality (HR = 2.19, 95% CI 1.07-4.46, p = 0.031). CONCLUSIONS: Elevated NT-proBNP is an independent predictor of mortality in tobacco smokers without known cardiovascular disease, conferring a 2.2 fold increased risk of death. Future studies should assess the ability of this biomarker to guide further diagnostic testing and to direct specific cardiovascular risk reduction inventions that may positively impact quality of life and survival.
No takes yet. Share an insight, caveat, or question.
Stamm et al. (2011) conducted a cohort in Tobacco smokers without known cardiovascular disease (n=796). Elevated NT-proBNP (≥49 pg/mL) vs. NT-proBNP <49 pg/mL was evaluated on Mortality (HR 2.19, 95% CI 1.07-4.46, p=0.031). Elevated NT-proBNP (≥49 pg/mL) independently predicted mortality in tobacco smokers without known cardiovascular disease, conferring a 2.19-fold increased risk of death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: